Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
Baraliakos X, Ranza R, Östör A, Ciccia F, Coates LC, Rednic S, Walsh JA, Douglas K, Gao T, Kato K, Song IH, Ganz F, Deodhar A. Baraliakos X, et al. Among authors: ostor a. Arthritis Res Ther. 2023 Apr 10;25(1):56. doi: 10.1186/s13075-023-03027-5. Arthritis Res Ther. 2023. PMID: 37038159 Free PMC article. Clinical Trial.
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
Navarro-Compán V, Baraliakos X, Magrey M, Östör A, Saffore CD, Mittal M, Song IH, Ganz F, Stigler J, Deodhar A. Navarro-Compán V, et al. Among authors: ostor a. Rheumatol Ther. 2023 Jun;10(3):679-691. doi: 10.1007/s40744-023-00536-2. Epub 2023 Feb 23. Rheumatol Ther. 2023. PMID: 36820984 Free PMC article.
Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, Vincent MS, Sun Q, Sikirica V, Winnette R, Qiu R, Li G, Feng G, Beebe JS, Martin DA. Mease P, et al. Among authors: ostor a. Arthritis Rheumatol. 2023 Aug;75(8):1370-1380. doi: 10.1002/art.42519. Epub 2023 Jun 22. Arthritis Rheumatol. 2023. PMID: 37194394 Free article. Clinical Trial.
Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.
Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Östör A, Ng KJ, Gerwien J, Zaremba-Pechmann L, Brnabic AJM, Fautrel B. Alten R, et al. Among authors: ostor a. Rheumatol Ther. 2023 Dec;10(6):1575-1595. doi: 10.1007/s40744-023-00597-3. Epub 2023 Sep 27. Rheumatol Ther. 2023. PMID: 37755648 Free PMC article.
The prevalence and impact of polypharmacy in rheumatology.
Lewis J, Östör AJK. Lewis J, et al. Among authors: ostor ajk. Rheumatology (Oxford). 2023 Oct 23;62(SI3):SI237-SI241. doi: 10.1093/rheumatology/kead307. Rheumatology (Oxford). 2023. PMID: 37871915 Review.
What is new in pharmacological treatment for osteoarthritis?
Gezer HH, Ostor A. Gezer HH, et al. Among authors: ostor a. Best Pract Res Clin Rheumatol. 2023 Jun;37(2):101841. doi: 10.1016/j.berh.2023.101841. Epub 2023 Jun 9. Best Pract Res Clin Rheumatol. 2023. PMID: 37302928 Review.
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos GD, Marrache F, Patel N, Dasgupta B; SAPHYR Investigators. Spiera RF, et al. N Engl J Med. 2023 Oct 5;389(14):1263-1272. doi: 10.1056/NEJMoa2303452. N Engl J Med. 2023. PMID: 37792612 Clinical Trial.
199 results